<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Barriers</title>
	<atom:link href="http://www.tapanray.in/tag/barriers/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Ticking Some Right Boxes Biosimilar Drugs’ Acceptance Gaining Steam in India</title>
		<link>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india</link>
		<comments>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/#comments</comments>
		<pubDate>Sun, 24 Sep 2023 06:26:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acceptance]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10828</guid>
		<description><![CDATA[Looking at a broader canvas, on September 19, 2023, a credible international report flashed a headline, ‘Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix.’ This is based on a survey of U.S. healthcare specialists, including 80 dermatologists, &#8230; <a href="http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Meeting India’s Unmet Biologic Drug Needs Some Global Synergy Evident &#8211; But Patients Need More</title>
		<link>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more</link>
		<comments>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/#comments</comments>
		<pubDate>Mon, 17 Jul 2023 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[Biosimilar. drugs]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10799</guid>
		<description><![CDATA[Many reports have vindicated the rapidly growing importance of biologic drugs in the treatment of a wide range of complex ailments. These include autoimmune diseases, cancers, hormonal irregularities, anemia, and to prevent various diseases such as vaccines, have drawn healthcare &#8230; <a href="http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access</title>
		<link>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access</link>
		<comments>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/#comments</comments>
		<pubDate>Mon, 09 Sep 2019 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Spirit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9701</guid>
		<description><![CDATA[For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. &#8230; <a href="http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Self-made Barriers To Business Transparency Impacting Drug Access</title>
		<link>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=self-made-barriers-to-business-transparency-impacting-drug-access</link>
		<comments>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/#comments</comments>
		<pubDate>Mon, 05 Aug 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[72nd]]></category>
		<category><![CDATA[AMF]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[Geneva]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[impact access]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orginal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resolution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[WHA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9655</guid>
		<description><![CDATA[A recently published book on pharma industry tried to expose the deceit behind many generic-drug manufacturing—and the consequent risks to global health. This publication is described as an ‘explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers &#8230; <a href="http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/self-made-barriers-to-business-transparency-impacting-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘One Indian, One Health Record’:  Is EHR A Tentative Intent?</title>
		<link>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=one-indian-one-health-record-is-ehr-a-tentative-intent</link>
		<comments>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/#comments</comments>
		<pubDate>Mon, 05 Nov 2018 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aadhar]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[cost quality]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[EHR]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[one health record]]></category>
		<category><![CDATA[One Indian]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[record]]></category>
		<category><![CDATA[Singapore]]></category>
		<category><![CDATA[speed]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tentative]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9247</guid>
		<description><![CDATA[The ongoing march of technology, at a scorching pace, transforming our everyday personal &#8211; working and social lives. This is palpable. In tandem, it is also making traditional processes of doing successful business less and less productive, over a period &#8230; <a href="http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/one-indian-one-health-record-is-ehr-a-tentative-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line</title>
		<link>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line</link>
		<comments>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/#comments</comments>
		<pubDate>Mon, 10 Jun 2013 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[blockbusters]]></category>
		<category><![CDATA[blocking]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[disparaging]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[entering]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Holland]]></category>
		<category><![CDATA[Impax]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NUT]]></category>
		<category><![CDATA[Opana]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[OxyContin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Purdue]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[TevaSante]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[ZydusCadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2234</guid>
		<description><![CDATA[To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the &#8230; <a href="http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
